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sting by EAbstract A simple and sensitive spectrophotometric method for the quantitative analysis of pyri-
methamine (PYM) in pharmaceutical formulations has been described. The method is based on the
formation of colored product between PYM and 1,2-naphthoquinone-4-sulfonate (NQS) at 60 C.
The reaction is followed spectrophotometrically by measuring the increase in absorbance at 483 nm
as a function of time. Under the optimized reaction condition, Beer’s law correlation for the absor-
bance (A) with PYM concentration (C) was obeyed in the range 12–40 lg mL1 the regression
equation for the calibration data was A= 0.704 + 0.0132C, with correlation coefﬁcient (0.996).
The molar absorptivity (e) was 5.8 · 103 L mol1 cm1. The limits of detection and quantiﬁcation
were 3.25 and 10.83 lg mL1, respectively. The proposed method was successfully applied to the
determination of PYM in pharmaceutical tablets with good accuracy and precision; the percentage
for PYM was 101.4 ± 1.47% for batch 20 and 100.4 ± 0.51% for batch 13. The results were in
good agreement with those obtained with the ofﬁcial high performance liquid chromatography
(HPLC) method.
ª 2012 University of Bahrain. Production and hosting by Elsevier B.V. All rights reserved..A. Elbashir).
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lsevier1. Introduction
Pyrimethamine (PYM), 5-(4-chlorophenyl)-6-ethyl-2,4-pyrimi-
dineamine (Fig. 1) is a drug widely used in the treatment of
parasitic diseases such as malaria and toxoplasmosis (Bosch-
Driessen et al., 2002).
Themechanism of action of PYM is the inhibition of dihydro-
folate reductase (DHFR), an essential enzyme responsible for the
conversion of folic acid into folinic acid in the nucleic acid biosyn-
thesis (Anderson, 2005). Somemajor drawbacks of PYR therapy
include a relatively weak inhibitory activity and severe side effects
such as nausea and neutropenia, which are caused by the low
selectivity toward the parasite enzyme (Katlama et al., 1996).
Literature survey reveals that various methods have been
reported for the analysis of PYM in pharmaceutical and bio-
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Figure 2 Absorption spectra of Pyrimethamine (20 lgml1)
against methanol (1). NQS (0.5% w/v) against water (2). And
the reaction product of primethamine (30 lgml1) with NQS
against reagent blank (3).
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Figure 1 Chemical structure of PYM.
Spectrophotometric determination of pyrimethamine (PYM) 33logical samples such as microbiological method (Weidekamm
et al., 1982), gas–liquid chromatography (Cala et al., 1972;
Jones et al., 1981; Midskov, 1984b), thin layer chromatogra-
phy (DeAngelis et al., 1975), spectrophotometry (Schmidt
et al., 1953; Sastry et al., 1986; Berzas Nevado et al., 1993;
Khalil et al., 2000; Onah and Odeiani, 2002; Zayed et al.,
2005; Nagaraja et al., 2010), ﬂuorimetry (Parimo, 1988) and
HPLC(Midskov, 1984a,b; Bergqvist and Eriksson, 1985;
Timm and Weidekamm, 1982; Edstein, 1948a,b) individually
and in combination dosage form with other drugs.
Spectrophotometry is considered the most convenient ana-
lytical technique, because of its inherent simplicity, low cost,
and wide availability in most quality control laboratories.
Spectrophotometric methods have been reported for PYM.
These methods were associated with some major drawbacks
such as laborious multiple extraction steps in the analysis by
ion-pair based methods (Khalil et al., 2000; Nagaraja et al.,
2010) Furthermore, the analytical reaction was long and thus
the procedure was time-consuming (Onah and Odeiani, 2002).
1,2-Naphthoquinone-4-sulfonate (NQS) has been used for
the determination of many compounds containing primary
amine group (Gallo-Martinez et al., 1998; Wang et al., 2004;
Saurina and Herna´ndez-Cassuo, 1993). Use of NQS as a col-
ored reagent for the determination of PYM by spectrophotom-
etry has not been reported yet. Therefore, the present work
was devoted to study the reaction between PYM and NQS
and employment of the reaction in the development of a simple
method for the determination of PYM in dosage form.
2. Material and methods
2.1. Instrumentation
All absorbance measurements were made with a Double beam
UV-1800 (SHIMADZU, Japan) ultraviolet–visible spectro-
photometer provided with matched 1-cm quartz cells and also
temperature controller was used for the spectrophotometric
measurements. pH meter model pH211 (HANNA, Italy).
Thermostatically controlled water bath type RE 220 (LAU-
DA, Germany).
2.2. Reagents and materials
Pyrimethamine (PYM) (AMIPHARMA Laboratories Ltd.,
Khartoum) were obtained and used as received; its purity
was 99.7%. A solution of 0.5% (w/v) of 1,4-naphthoqui-
none-4-sulfonate (NQS) (Aldrich chemical Co., St. Louis,
USA) was prepared by dissolving 125 mg in 25 mL double dis-
tilled water. The solution was freshly prepared and protected
from light during use. Buffer solution of pH 13.0 was prepared
by mixing 25 mL solution of KCl (0.2 M) and 66 mL solutionof NaOH (0.2 M) in 100 mL volumetric ﬂask, and adjusted by
the pH meter. Other buffer solutions of different pH values
were also prepared. Amifan tablets were kindly donated by
AMIPHARMA Laboratories Ltd. (Sudan, Khartoum).
Milli-Q water was used for preparing all solutions used.
2.3. Preparation of standard and sample solution
2.3.1. PYM standard solutions
An accurately weighed 10 mg of PYM was dissolved in meth-
anol, transferred into a 10 mL standard ﬂask and completed to
the mark with methanol. This stock solution was further di-
luted with the same solvent to obtain working solutions in
the range 6–60 lgmL1.
2.3.2. Tablets sample solution
Twenty tablets were weighed, and ﬁnely powdered. An accu-
rately weighed quantity of the powdered tablets equivalent to
4.25 mg of PYM was transferred into a 25 mL calibrated ﬂask,
and dissolved in methanol. The prepared solutions were di-
luted quantitatively with methanol to obtain a suitable concen-
tration for the analysis.
2.3.3. General recommended procedure
Accurately measured 1 mL of PYM solution containing 12–
40 lgmL1 was transferred into a 10 mL volumetric ﬂask.
3 mL of buffer solution pH (13.0) was added, followed by
1 mL of NQS solution (0.5%, w/v). The reaction solution
was allowed to proceed at 60 C for 15 min. The reaction mix-
ture was completed to volume with water, and the resulting
solution was measured at 483 nm against reagent blank.
2.4. Determination of PYM by HPLC
According to the United States Pharmacopoeia, PYM was
determined in two batches number (batch number 20 and
13). The analysis was performed on a Phenomenex C18-col-
umn; 5 lm (250 mm 4.6 mm i.d.) with a guard column
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Figure 3 Effect of NQS concentration on the reaction of PYM
with NQS. PYM (40 lg/ml): 1 ml; buffer solution (pH 13.0); 3 ml;
temperature 60 C; reaction time: 15 min.
Table 1 Parameters for the performance of the proposed
method.
Parameter Value
Measurement wavelength (nm) 483
Linear range (lg mL1) 12–40
Intercept 0.704
Standard deviation of the intercept 0.014
Slope 0.013
Standard deviation of the slope 0.001
Correlation coeﬃcient (r) 0.996
Limit of detection, LOD (lg mL1) 3.25
Limit of quantiﬁcation, LOQ (lg mL1) 10.83
Molar absorptivity, e (1 mol1 cm1) 5.8 · 103
34 A.A. Elbashir, A.H.E. Elwagee(4.0 mm · 3.0 mm i.d.). The mobile phase consisting of 80%
glacial acetic acid (1:100), 20% acetonitrile and 500 lL trieth-
ylamine was delivered as an isocratic elution at a ﬂow rate of
2 mL/min and 10 lL of the sample was injected. Before use
the mobile phase was degassed by an ultrasonic bath and ﬁl-
tered by a Millipore vacuum ﬁlter system equipped with a
0.45 ml HV ﬁlter.
3. Results and discussion
3.1. Optimization
The absorption spectrum of the reaction product between
NQS and PYM with an absorption maximum at 480 nm is
shown in Fig. 2. Clearly from this ﬁgure a broad absorption
band at longer wavelengths is obtained for the reaction be-
tween NQS and PYM.
The optimum conditions for the development of method
were established by varying the parameters one at a time while
keeping the others ﬁxed and observing the effect produced on
the absorbance of the colored product. In order to establish
experimental conditions, the effect of various parameters such
as concentration of NQS, pH, temperature, and time of heat-
ing were studied.
The effect of NQS concentration was studied over the range
0.1–1.5 w/v% as shown in Fig. 3. Increasing the concentration
of NQS results in more products up to an amount of 0.5%Cl
N
N
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H2N
+
O
O
SO3Na
Figure 4 Scheme for the reactionafter which the absorbance remained almost constant. There-
fore a concentration of 0.5% NQS was considered optimum.
The inﬂuences of pH on the absorbance of product I was
investigated in the range 1.0 to 14. At pH 1.0–7.0, the
absorbance of the product is close to 0, indicating that un-
der high acidity, PYM does not react with NQS. The possi-
ble reason may be that the amino group (NH2) of PYM is
protonated (pka = 7.26 G.S. La´zaro et al., 2008) and con-
verted into protonated amine salt ðNHþ3 Þ. So it loses nucle-
ophilic capability for 4-sodium sulfonate of NQS, and the
nucleophilic substitution reaction cannot take place easily.
At pH > 10.0, the absorbance of the solution increases rap-
idly up to pH 13.0. It may be that protonated amine salt
ðNHþ3 Þ of PYM turns into amino group (NH2) again
when the acidity of the solution becomes low. The higher
the pH, the more effectively the protonated amino group re-
moves the proton, and more easily the nucleophilic substitu-
tion reaction happens. At pH 13.0, the absorbance reaches
its maximum; in other words, the degree of the nucleophilic
substitution reaction is also maximal. At pH> 13.0, the
absorbance of solution decreases sharply again. Presumably
it may be that the increase of hydroxide ion holds back
the nucleophilic substitution reaction between PYM and
the chromogenic reagent. Consequently, the absorbance of
the solution reduces. In order to keep the high sensitivity
for the determination of PYM, pH 13.0 was selected for
optimal experimental conditions. Reaction of NQS with
compound bearing primary amines at pH 13.0 was reported
(Li and Zhang, 2008).
The effect of temperature on the reaction was studied in the
range 20–80 C. About 60 C was found to be optimal for
maximum color development.Cl
N
N
NH
H2N
O
O
+ NaHSO3
pathway of PYM with NQS.
Table 2 Recovery studies for the determination of PYM, by the proposed method.
Sample No. +SD Sample content (lgmL1) Pyr. added (lgmL1) Found Recovery (%)
1 10 14 14.0 100.0 ± 0.01
2 – 18 18.3 101.7 ± 0.03
3 – 26 26.1 100.5 ± 0.01
4 – 32 42.8 101.9 ± 0.09
Table 3 Inﬂuence of small variation in the assay conditions
on the analytical performance of the proposed spectrophoto-
metric method for the determination of pyr. using NQS
reagent.
Parameters Recovery (%± SD)
Recommended conditions 101.4 ± 1.5
NQS concentration (%, w/v) 0.45 100.2 ± 0.1
NQS concentration (%, w/v) 0.55 99.7 ± 0.1
Buﬀer (pH) 12.75 100.8 ± 0.1
Buﬀer (pH) 13.25 99.7 ± 0.3
Temperature (C) 58 99.6 ± 0.2
Temperature (C) 60 99.9 ± 0.1
Reaction time (min) 14 98.4 ± 0.2
Reaction time (min) 100.5± 0.1
Spectrophotometric determination of pyrimethamine (PYM) 35The inﬂuence of the time of heating was also investigated in
the range 5–30 min. The experimental results show that heat-
ing in the range 15–20 min gave the optimal values in kinetic
studies. The color product was stable for at least two days at
room temperature.
From the above experiments, the optimized conditions used
for the assay were: NQS concentration 0.5% w/v, buffer (pH
13.0), reaction time 20 min and temperature 60 C.
Under the optimum conditions, the stoichiometry of the reac-
tion between PYM and NQS was studied by the Job’s (1964)
method. The symmetrical bell shape of Job’s plot indicated that
the ratio of PYM:NQS is 1:1. Based on this ratio, the reaction
pathway was proposed to proceed as shown in Fig. 4.
3.2. Analytical methods validation
As can be seen from Table 1, linear relationship was found be-
tween absorbance at kmax (483) and the concentration of the
PYM in the range 12–40 lg mL1. The regression equation
was found as A= 0.0132C + 0.704 (r2 = 0.996). The limits
of detection (LOD) and limit of quantitation (LOQ) were
determined using the formula:LOD or LOQ= KS.D.a/b,
where k= 3 for LOD and 10 for LOQ, SDa is the standard
deviation of the intercept, and b is the slope.
The accuracy of the proposed method was carried out by
applying standard addition technique. A different amount of
standard solution was added to a known concentration of
the drug sample. The average percent recoveries obtained in
range 100.04–101.9. Table 2.
Robustness was examined by evaluating the inﬂuence of
small variation of method variables including the concentra-
tion of analytical reagent and reaction time on the perfor-
mance of the proposed methods. In these experiments, one
parameter was changed whereas the others were kept un-
changed, and the recovery percentage was calculated each
time. It was found that small variation of method variables
did not signiﬁcantly affect the procedures; recovery values
were 98.43101.40 (Table 3).
3.3. Application to the pharmaceutical dosage forms
PYM tablets were subjected to the analysis by the proposed as
well as with the ofﬁcial HPLC method (United States pharma-Table 4 Analysis of PYM containing dosage forms by the propose
Dosage form Recovery %+RSD (n= 5)
Proposed
AMIFAN batch 20 101.4 ± 1.5
AMIFAN batch 13 100.4 ± 0.5
The tabulated values for t and f at 95% conﬁdence limit are 2.78 and 6.2copeia, 2006) and the obtained results were statistically
compared with each other. The label claim percentage was
101.40 ± 1.47 and 102.38 ± 0.51 for batch 20 and batch 13
respectively (Table 4). With respect to t- and F-tests, no signif-
icant differences were found between the calculated and theoret-
ical values of both the proposed and the reported methods at
95% conﬁdence level. This indicated similar accuracy and
precision in the analysis of PYM in tablets. Common tablet
excipients such as talc, lactose, starch, avisil, gelatine and
magnesium stearate did not interfere with the assay.
4. Conclusions
The present paper described the evaluation of NQS as an ana-
lytical reagent in the development of simple, sensitive, and
accurate spectrophotometric methods, for the determination
of PYM in pharmaceutical formulations. The described meth-
od is superior to the previously reported spectrophotometric
methods in terms of simplicity and sensitivity. The proposed
method has comparable analytical performances and is devoid
of any potential interference. This gives the advantage of ﬂex-
ibility in performing the analysis on any available instrument.
Therefore, this method can be recommended for the routine
analysis of PYM in quality control laboratories.d and ofﬁcial HPLC methods (United States Pharmacopoeia).
t-value f-value
Oﬃcial
102.5 ± 1.4 1.21 1.09
99.7 ± 0.5 2.40 1.18
6, respectively.
36 A.A. Elbashir, A.H.E. ElwageeReferences
Anderson, A.C., 2005. Targeting DHFR in parasitic protozoa. Drug
Discov. Today 10, 121–128.
Bergqvist, Y., Eriksson, M., 1985. Simultaneous determination of
pyrimethamine and sulphadoxine in human plasma by high-
performance liquid chromatography. Trans. R. Soc. Trop. Med.
Hyg. 79, 297–301.
Berzas Nevado, J.J., Lemus Gallego, J.M., Castaneda Penalvo, G.,
1993. Spectral ratio derivative spectrophotometric determination of
sulphaquinoxaline and pyrimethamine in veterinary formulations.
J. Pharm. Biomed. Anal. 11, 601–607.
Bosch-Driessen, L.H., Verbraak, F.D., Suttorp-Schulten, M.S.A., van
Ruyven, R.L.J., Klok, A.M., Hoyng, C.B., Rothova, A., 2002. A
prospective, randomized trial of pyrimethamine and azithromycin
vs pyrimethamine and sulfadiazine for the treatment of ocular
toxoplasmosis. Am. J. Ophthalmol. 134, 34–40.
Cala, P.C., Trenner, N.R., Buhs, R.P., Downing Jr., G.V., Smith, J.L.,
Vandenheuvel III, W.J.A., 1972. Gas chromatographic determina-
tion of pyrimethamine in tissue. J. Agric. Food. Chem. 20, 334–337.
DeAngelis, R.L., Simmons, W.S., Nichol, C.A., 1975. Quantitative
thin layer chromatography of pyrimethamine and related
diaminopyrimidines in body ﬂuids and tissues. J. Chromatogr.
106, 41–49.
Edstein, M., 1984a. Quantiﬁcation of antimalarial drugs. I. Simulta-
neous measurement of sulphadoxine. N4-acetylsulphadoxine and
pyrimethamine in human plasma. J. Chromatogr. B Biomed. Appl.
305, 502–507.
Edstein, M., 1984b. Quantiﬁcation of antimalarial drugs II. Simulta-
neous measurement of dapsone, monoacetyldapsone and pyrimeth-
amine in human plasma. J. Chromatogr. B Biomed. Appl. 307,
426–431.
Gallo-Martinez, L., Sevillano-Cabeza, A., Camp´ıns-Falc, P., Bosch-
Reig, F., 1998. A new derivatization procedure for the determina-
tion of cephalexin with 1,2-naphthoquinone 4-sulphonate in
pharmaceutical and urine samples using solid-phase extraction
cartridges and UV–visible detection. Anal. Chim. Acta 370,
115–123.
Job, P., 1964. Advanced Physicochemical Experiments, second ed.
Oliner and Boyd, Edinburgh, p. 54.
Jones, C.R., Ryle, P.R., Weatherley, B.C., 1981. Measurement of
pyrimethamine in human plasma by gas–liquid chromatography. J.
Chromatogr. 224, 492–495.
Khalil, S.M., Mohamed, G.G., Zayed, M.A., Elqudaby, H.M., 2000.
Spectrophotometric determination of chloroquine and pyrimeth-
amine through ion-pair formation with molybdenum and thiocy-
anate. Microchem. J. 64, 181–186.
Katlama, C., De Wit, S., O’Doherty, E., van Glabeke, M., Clumeck,
N., 1996. Pyrimethamine–clindamycin vs. pyrimethamine–sulfadi-
azine as acute and long-term therapy for toxoplasmic encephalitis
in patients with AIDS. Clin. Infect. Dis. 22, 268–275.La´zaro, G.S., Meneses Jr., A.L., Lopes de Macedo, O.F., Gimenez,
I.d.F., da Costa Jr., N.B., Barreto, L.S., Almeida, L.E., 2008.
Interaction of pyrimethamine and sulfadiazine with ionic and
neutral micelles: electronic absorption and ﬂuorescence studies.
Colloids Surf. A: Physicochem. Eng. Aspects 324, 98–104.
Li, Q., Zhang, H., 2008. A novel spectrophotometric method for the
determination of aminophylline in pharmaceutical samples in the
presence of methanol. Spectrochim. Acta Part A 70, 284–289.
Midskov, C., 1984a. Rapid gas chromatographic determination of
pyrimethamine in human plasma and urine. J. Chromatogr. B
Biomed. Appl. 306, 388–393.
Midskov, C., 1984b. High-performance liquid chromatographic assay
of pyrimethamine, sulfadoxine and its N4-acetyl metabolite in
serum and urine after ingestion of Suldox. J. Chromatogr. B
Biomed. Appl. 308, 217–227.
Nagaraja, P., Shrestha, A.K., Shivakumar, A., Gowda, A.K., 2010.
Spectrophotometric determination of chloroquine, pyrimethamine
and trimethoprim by ion pair extraction in pharmaceutical formu-
lation and urine. J. Food Drug Anal. 18, 239–248.
Onah, J.O., Odeiani, J.E., 2002. Simultaneous spectrophotometric
determination of sulfadoxine and pyrimethamine in pharmaceutical
formulations. J. Pharm. Biomed. Anal. 30, 851–857.
Parimo, P., 1988. Determination of pyrimethamine in drug prepara-
tion by ﬂuorimetry. Indian J. Pharm. Sci. 50, 114–117.
Sastry, B.S., Venkata Rao, E., Tumuru, M.K., Sastry, C.S.P., 1986. A
new spectrophotometric method for the estimation of primaquine
using MBTH. Indian J. Pharm. Sci. 48, 190–192.
Saurina, J., Herna´ndez-Cassuo, S., 1993. Continuous-ﬂow spectro-
photometric determination of amino acids with 1,2-naphthoqui-
none-4-sulphonate reagent. Anal. Chim. Acta 283, 414–420.
Schmidt, L.H., Hughes, H.B., Schmidt, I.G., 1953. The pharmacolog-
ical properties of 2, 4-diamino-5-p-chlorophenyl-6-ethylpyrimidine,
daraprim. J. Pharmacol. Exp. Ther. 107, 92–130.
Timm, U., Weidekamm, E., 1982. Determination of pyrimethamine in
human plasma after administration of fansidar or fansidar-meﬂo-
quine by means of high-performance liquid chromatography with
ﬂuorescence detection. J. Chromatogr. 230, 107–114.
United States Pharmacopoeia, 2006, 29-NF23, Pharmacopoeial Con-
vention: Rockville, MD; Vol. 727, 2030.
Wang, H.Y., Xu, L.X., Xiao, Y., Han, J., 2004. Spectrophotometric
determination of dapsone in pharmaceutical products using sodium
1, 2-naphthoquinone-4-sulfonic as the chromogenic reagent. Spec-
trochim. Acta Part A 60, 2933–2939.
Weidekamm, E., Plozza-Nottebrock, H., Forgo, I., Dubach, U.C.,
1982, B. World Health Organ 60, 115.
Zayed, M.A., Shaban, M.K., Hoda, M.El., 2005. Spectrophotometric
study of the reaction mechanism between DDQ p- and iodine r-
acceptors and chloroquine and pyrimethamine drugs and their
determination in pure and in dosage forms. Spectrochim. Acta Part
A 62, 461–465.
